Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines

Our previous preclinical studies and a Phase I clinical trial DP6-001 have indicated that a polyvalent Env formulation was able to elicit broadly reactive antibody responses including low titer neutralizing antibody responses against viral isolates of subtypes A, B, C and AE. In the current report,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Hum Vaccin Immunother
Asıl Yazarlar: Wang, Shixia, Chou, Te-hui, Hackett, Anthony, Efros, Veronica, Wang, Yan, Han, Dong, Wallace, Aaron, Chen, Yuxin, Hu, Guangnan, Liu, Shuying, Clapham, Paul, Arthos, James, Montefiori, David, Lu, Shan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2017
Konular:
Research Papers
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5718816/
https://ncbi.nlm.nih.gov/pubmed/28933684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2017.1380137
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller